Nine for 2021: Addressing the pandemic legacyIn this second ‘Nine for 2021‘ article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact Share XNine for 2021: Addressing the pandemic legacyhttps://pharmaphorum.com/views-analysis-sales-marketing/nine-for-2021-pandemic-legacy/
Novartis set to overcome $14 billion patent cliff say analystsNovartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition Share XNovartis set to overcome $14 billion patent cliff say analystshttps://pharmaphorum.com/news/novartis-set-to-overcome-14-billion-patent-cliff-analyst/
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarNovartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its Share XFDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarhttps://pharmaphorum.com/news/novartis-lucentis-could-face-biosimilar-competition/
COVID-19 tests prop up Roche as US biosimilars bite in Q3Roche’s pharmaceutical revenues have been hit by falling sales in its pharma division in Q3 but a spike Share XCOVID-19 tests prop up Roche as US biosimilars bite in Q3https://pharmaphorum.com/news/us-biosimilars-bite-into-roches-pharma-revenues/
Amgen’s cancer biosimilars stay on US market as court battle with Roche endsAmgen has scored yet another home run in the US courts, this time seeing off a legal challenge Share XAmgen’s cancer biosimilars stay on US market as court battle with Roche endshttps://pharmaphorum.com/news/amgens-cancer-biosimilars-stay-on-us-market-as-court-battle-with-roche-ends/
Breaking policy and perceptual barriers: BiosimilarsExperts from Research Partnership analyse the company’s Therapy Watch data to identify how market access policy has impacted Share XBreaking policy and perceptual barriers: Biosimilarshttps://deep-dive.pharmaphorum.com/magazine/market-access-2020/breaking-policy-and-perceptual-barriers-biosimilars/
Deep Dive: Market Access – Breaking BarriersIn this issue of Deep Dive we look at the changing landscape for pharma market access and start Share XDeep Dive: Market Access – Breaking Barriershttps://pharmaphorum.com/views-analysis-market-access/deep-dive-market-access/
Merck & Co spin off could start a trend in big pharmaMerck & Co’s strategy to spin off its older drugs and biosimilars into a new stand-alone business will Share XMerck & Co spin off could start a trend in big pharmahttps://pharmaphorum.com/news/merck-cos-spin-off-closely-watched-by/
3 key trends shaping the immunology marketFrom an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an Share X3 key trends shaping the immunology markethttps://pharmaphorum.com/views-analysis-market-access/3-key-trends-shaping-the-immunology-market/
